ESR1 and breast cancer: Preclinical studies showed that ENT treatment restores letrozole responsiveness of ERα-negative tumors providing a strong rationale for clinical evaluation of combinatorial therapy of ENT and letrozole to treat ERα-negative and endocrine-resistant breast cancers [99].